APSV in Vaccinia Naive Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00050518 |
Recruitment Status :
Completed
First Posted : December 13, 2002
Last Update Posted : August 27, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Smallpox | Biological: Aventis Pasteur Smallpox Vaccine | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 444 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Primary Purpose: | Prevention |
Official Title: | A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. |
Actual Primary Completion Date : | February 2003 |
Actual Study Completion Date : | February 2003 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 32 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA:
- Adequate renal function defined as a serum creatinine 1.5 mg/dL; urine protein < 100mg/ dL or trace or negative proteinuria (by dipstick), and a calculated creatinine clearance >55 mL/min. Formula for calculations is contained within the Manual of Procedures.
(Note: Renal function is measured to ensure that subjects could meet criteria for use of cidofovir if needed).
- Age 18-32 (children are excluded due to concerns of safety, including autoinoculation).
- Willing to sign informed consent.
- Availability for follow-up for planned duration of the study (56 days following the last vaccination).
- Acceptable medical history by screen evaluation form and brief assessment.
- Absence of a typical vaccinia scar and negative history of smallpox vaccination.
- Negative urine or serum pregnancy test for women of childbearing potential.
- If the volunteer is female and of childbearing potential, she agrees to use acceptable contraception, and not become pregnant for the duration of the study. (Acceptable contraception includes implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner).
- Negative ELISA for HIV or negative Western blot for subjects who have a positive ELISA and have participated in an HIV vaccine trial.
- Negative hepatitis B surface antigen and negative antibody to hepatitis C virus.
- Negative urine glucose by dipstick.
- ALT < 1.5 times institutional upper limit of normal.
EXCLUSION CRITERIA:
- Allergies to any component of the vaccines (e.g., polymyxin B sulfate, dihydrostreptomycin sulfate, chlorotetracycline hydrochloride).
- History of immunodeficiency.
- Serology positive for HIV, hepatitis B, or hepatitis C at the screening visit.
- Known or suspected impairment of immunologic function including, but not limited to clinically significant liver disease.
- Diabetes mellitus.
- Moderate to severe kidney impairment.
- Malignancy with the exception of squamous cell or basal cell skin cancer.
- Autoimmune disease.
- Use of immunosuppressive medication.
- Corticosteroid nasal sprays are permissible.
- Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol.
- History of illegal injection drug use.
- Live attenuated vaccines within 60 days of study.
- Use of experimental agents within 30 days prior to study.
- Any history of vaccination with any vaccinia vectored or other pox vectored experimental vaccine.
- Smallpox vaccination since 1990 (Vaccinia experience cohorts).
- Typical vaccinia scar or history of smallpox vaccination (Vaccinia naive cohorts only).
- Receipt of blood products or immunoglobulin in the past 6 months.
- Recent donation of the equivalent of a pint of blood within the 30 days prior to enrollment.
- Acute febrile illness (100.5 F) on the day of vaccination.
- Pregnant or lactating women.
- Eczema of any degree or history of eczema.
- History of exfoliative skin disorders/conditions.
- Any acute skin disorders of large magnitude, e.g., laceration requiring sutures, burn greater than 2x2 cm.
- Household contacts/sexual contacts with, or close and frequent occupational exposure to, any of the following: pregnant women, children < 12 months of age, people with eczema or history of eczema, people with any of the skin disorders/conditions previously listed, people with immunodeficiency disease or use of immunosuppressive medications.
- Any condition which, in the opinion of the investigator, might interfere with study objectives.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00050518
United States, Iowa | |
University of Iowa - Iowa City IA | |
Iowa City, Iowa, United States, 52242 | |
United States, Ohio | |
Cincinnati Children's Hospital Med Ctr | |
Cincinnati, Ohio, United States, 45229 | |
University of Cincinnati | |
Cincinnati, Ohio, United States, 45267-05 | |
United States, Tennessee | |
Vanderbilt University | |
Nashville, Tennessee, United States, 37232-26 |
ClinicalTrials.gov Identifier: | NCT00050518 |
Other Study ID Numbers: |
02-054 |
First Posted: | December 13, 2002 Key Record Dates |
Last Update Posted: | August 27, 2010 |
Last Verified: | March 2010 |
Smallpox Aventis Pasteur Vaccine |
Vaccinia Smallpox Poxviridae Infections DNA Virus Infections Virus Diseases |